BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1501 related articles for article (PubMed ID: 26501844)

  • 1. Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status.
    Miglioretti DL; Zhu W; Kerlikowske K; Sprague BL; Onega T; Buist DS; Henderson LM; Smith RA;
    JAMA Oncol; 2015 Nov; 1(8):1069-77. PubMed ID: 26501844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy.
    Kerlikowske K; Zhu W; Hubbard RA; Geller B; Dittus K; Braithwaite D; Wernli KJ; Miglioretti DL; O'Meara ES;
    JAMA Intern Med; 2013 May; 173(9):807-16. PubMed ID: 23552817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biennial versus annual mammography and the risk of late-stage breast cancer.
    White E; Miglioretti DL; Yankaskas BC; Geller BM; Rosenberg RD; Kerlikowske K; Saba L; Vacek PM; Carney PA; Buist DS; Oestreicher N; Barlow W; Ballard-Barbash R; Taplin SH
    J Natl Cancer Inst; 2004 Dec; 96(24):1832-9. PubMed ID: 15601639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of mammography screening interval on breast cancer diagnosis by menopausal status and BMI.
    Dittus K; Geller B; Weaver DL; Kerlikowske K; Zhu W; Hubbard R; Braithwaite D; O'Meara ES; Miglioretti DL;
    J Gen Intern Med; 2013 Nov; 28(11):1454-62. PubMed ID: 23760741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.
    Kerlikowske K; Miglioretti DL; Ballard-Barbash R; Weaver DL; Buist DS; Barlow WE; Cutter G; Geller BM; Yankaskas B; Taplin SH; Carney PA
    J Clin Oncol; 2003 Dec; 21(23):4314-21. PubMed ID: 14645420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer.
    Engmann NJ; Golmakani MK; Miglioretti DL; Sprague BL; Kerlikowske K;
    JAMA Oncol; 2017 Sep; 3(9):1228-1236. PubMed ID: 28152151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model.
    Gangnon RE; Sprague BL; Stout NK; Alagoz O; Weedon-Fekjær H; Holford TR; Trentham-Dietz A
    Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):905-12. PubMed ID: 25787716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annual or biennial mammography screening for women at a higher risk with a family history of breast cancer: prognostic indicators of screen-detected cancers in New South Wales, Australia.
    Randall D; Morrell S; Taylor R; Hung WT
    Cancer Causes Control; 2009 Jul; 20(5):559-66. PubMed ID: 19015941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening?
    Erbas B; Amos A; Fletcher A; Kavanagh AM; Gertig DM
    Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1569-73. PubMed ID: 15466971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials.
    Neuhouser ML; Aragaki AK; Prentice RL; Manson JE; Chlebowski R; Carty CL; Ochs-Balcom HM; Thomson CA; Caan BJ; Tinker LF; Urrutia RP; Knudtson J; Anderson GL
    JAMA Oncol; 2015 Aug; 1(5):611-21. PubMed ID: 26182172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cumulative 6-Year Risk of Screen-Detected Ductal Carcinoma In Situ by Screening Frequency.
    Sprague BL; Chen S; Miglioretti DL; Gard CC; Tice JA; Hubbard RA; Aiello Bowles EJ; Kaufman PA; Kerlikowske K
    JAMA Netw Open; 2023 Feb; 6(2):e230166. PubMed ID: 36808238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammographic density, response to hormones, and breast cancer risk.
    Boyd NF; Melnichouk O; Martin LJ; Hislop G; Chiarelli AM; Yaffe MJ; Minkin S
    J Clin Oncol; 2011 Aug; 29(22):2985-92. PubMed ID: 21709206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First epidemiological analysis of breast cancer incidence and tumor characteristics after implementation of population-based digital mammography screening.
    Weigel S; Batzler WU; Decker T; Hense HW; Heindel W
    Rofo; 2009 Dec; 181(12):1144-50. PubMed ID: 19859859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
    Glass AG; Lacey JV; Carreon JD; Hoover RN
    J Natl Cancer Inst; 2007 Aug; 99(15):1152-61. PubMed ID: 17652280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.
    Meshkat B; Prichard RS; Al-Hilli Z; Bass GA; Quinn C; O'Doherty A; Rothwell J; Geraghty J; Evoy D; McDermott EW
    Breast; 2015 Jun; 24(3):278-82. PubMed ID: 25771080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer.
    Buist DSM; Abraham L; Lee CI; Lee JM; Lehman C; O'Meara ES; Stout NK; Henderson LM; Hill D; Wernli KJ; Haas JS; Tosteson ANA; Kerlikowske K; Onega T;
    JAMA Intern Med; 2018 Apr; 178(4):458-468. PubMed ID: 29435556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in incidence and detection of advanced breast cancer at biennial screening mammography in The Netherlands: a population based study.
    Nederend J; Duijm LE; Voogd AC; Groenewoud JH; Jansen FH; Louwman MW
    Breast Cancer Res; 2012 Jan; 14(1):R10. PubMed ID: 22230363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates?
    Braithwaite D; Zhu W; Hubbard RA; O'Meara ES; Miglioretti DL; Geller B; Dittus K; Moore D; Wernli KJ; Mandelblatt J; Kerlikowske K;
    J Natl Cancer Inst; 2013 Mar; 105(5):334-41. PubMed ID: 23385442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmenopausal estrogen replacement therapy is associated with adverse breast cancer prognostic indices.
    LeBlanc ES; Viscoli CM; Henrich JB
    J Womens Health Gend Based Med; 1999; 8(6):815-23. PubMed ID: 10495262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk.
    Kerlikowske K; Ichikawa L; Miglioretti DL; Buist DS; Vacek PM; Smith-Bindman R; Yankaskas B; Carney PA; Ballard-Barbash R;
    J Natl Cancer Inst; 2007 Mar; 99(5):386-95. PubMed ID: 17341730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.